ArticleFrontiers in immunology2024

TACE plus lenvatinib and tislelizumab for intermediate-stage hepatocellular carcinoma beyond up-to-11 criteria: a multicenter cohort study.

Song Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.